As the field of hepatology continues to grow, more health care professionals with little or no experience in the treatment of patients with HCV are being used to provide competent patient care.
At the same time, providers in communities or facilities with limited hepatology or specialty clinics may have fewer opportunities to engage in real patient cases, or multi-disciplinary case discussions regarding patients with HCV. These providers need to be able to evaluate and identify patients for potential therapeutic treatment, and potentially initiate treatment when appropriate.
What is ACT-on-HCV?
AASLD Curriculum & Training (ACT) is an initiative that provides strategies and mentoring for managing HCV. It is designed to increase the confidence and competence of health care professionals who are new to providing care for patients with HCV.
ACT-on-HCV curriculum comprises two main components.
- 5 online interactive, narrated modules 30 to 45 minutes in length
- Pre- and post-test questions for each module
- Final online multiple choice evaluation
Experiential Component "ACTual"
- Download the Experiential Log
Each trainee is required to log a minimum of 40 hours of clinical or direct experiences specifically with patients with viral hepatitis. These experiences are to be verified by the trainee’s Expert Resource, who is an experienced clinician / hepatologist. The expert can be self-identified, or upon request (via the participant’s registration), a link to a potential Expert Resource (AASLD member) will be provided to the trainee.
- Participate in Community Teleconferences/Web-based
Trainees will be required to attend a minimum of five (5) ACT-on-HCV Community Teleconferences/Web-based conference calls with other Expert Resources and Trainees during the training period. Trainees will be required to present two (2) cases to this group, optimally with their Expert Resource in attendance.
- Direct Case Management
As part of the experiential component, a minimum of two (2) cases related to the direct management of patients with HCV will be required as part of the successful completion of the experiential component.
- Expert Resource Check-ins
In addition to review and support of two (2) patient cases by the trainee, the Expert Resource is required to provide interim "check-ins", review a trainee’s progress, and sign-off on the experiential log.
Upon completion of the experiential log and obtaining signatures from the Expert Resource, the trainee will scan and upload their log for verification. Upon verification a certificate of completion will be issued.
What are the Key Topic Areas?
- A general overview of HCV
- Genotyping and predictors of response
- Patient selection
- Initiating HCV treatment and the first eight weeks
- Managing side effects of therapy
What are the Requirements to obtain a Certificate of Completion for the ACT-on-HCV Curriculum?
- Trainees must score an 80% on each of the 5 modules in order to pass.
- Trainee must complete and verify with the Expert Resource the experiential component of curriculum.
- Upon verification of all of the online and experiential component requirements, the trainee will receive a Certificate of Completion for the ACT-on-HCV Curriculum.
What are the Requirements for Successful Completion of CME/CE Credits?
In order to receive credit, participants must view and engage in the individual online modules, complete the pre- and post-tests, and the module evaluation form. This program is offered free of charge for educational purposes to health care professionals and others interested in the treatment of patients with hepatitis C.
- Release date: November 10, 2012
- Updated date: November 10, 2013
- Expiration date: November 10, 2014
- Time to complete each module: 45 minutes
AASLD designates this enduring material for a maximum of 5.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
IAHB designates this enduring material for a maximum of 3.75 contact hours.
Module 2: HCV Genotyping and Predictors of Response
- Discuss the natural history of hepatitis C infection
- Describe treatment guidelines in genotype 1 infection with direct-acting anti-viral agents
Module 3: Patient Selection
- Understand the role of hepatitis C genotyping in the treatment of chronic hepatitis C
- Identify both patient and viral factors that affect response to hepatitis C antiviral therapy
- Predict response rates in patients who did not achieve a sustained virological response (SVR) to prior therapy
- Describe a patient's chances of achieving SVR
Module 4: Initiating HCV Treatment: The first 8 Weeks
- Identify 3 barriers to treatment of chronic hepatitis C
- Identify 3 factors that can negatively impact a patient’s response to treatment
- Demonstrate understanding of the role of a multidisciplinary team in the treatment of patients with chronic hepatitis C
Module 5: Managing Side Effects of Therapy
- Describe the proper use and management of hepatitis C protease inhibitors, peginterferon and ribavirin for the treatment of chronic HCV genotype 1 infection
- Identify monitoring and laboratory tests relevant to HCV managment
- Develop strategies to minimize adverse effects related to HCV antiviral treatment
Module 6: A Review of Sofosbuvir and Simeprevir
- Discuss interventions for side effect management during hepatitis C treatment
1. Review phase III data on both sofosbuvir and simeprevir
2. Review package inserts and treatment guidelines for sofosbuvir and simeprevir